Daniel Loeb’s GeneDx Holdings WGS Stock Holding History

Daniel Loeb’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-168,030	Closed	-$4.87M	–	55
2022 Q3	$4.87M	Hold	168,030	–	–	0.09%	41
2022 Q2	$6.99M	Buy	168,030 +37,878	+29%	+$2.57M	0.17%	39
2022 Q1	$13.2M	Hold	130,152	–	–	0.17%	43
2021 Q4	$19.2M	Buy	130,152 +45,455	+54%	+$10.2M	0.13%	51
2021 Q3	$21.2M	Buy	84,697 +45,455	+116%	+$15.6M	0.12%	55
2021 Q2	$18.1M	Hold	39,242	–	–	0.11%	62
2021 Q1	$19.3M	Buy	+39,242	New	+$20.4M	0.13%	63

Other funds holding WGS

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Daniel Loeb's WGS Position: Q4 2022 in Review

Daniel Loeb sold out of GeneDx Holdings (WGS) in Q4 2022, closing a stake of 168,030 shares — an estimated $4.87M sold.

Daniel Loeb first reported a position in WGS in Q1 2021 and held it in 7 quarters. The position peaked at $21.2M in Q3 2021. 86 funds tracked by Wall St. Rank hold WGS as of Q4 2022.

Daniel Loeb reported no remaining GeneDx Holdings position as of Q4 2022 after selling out during the quarter.
Daniel Loeb sold 168,030 GeneDx Holdings shares in Q4 2022, an estimated $4.87M.
Daniel Loeb first reported a position in GeneDx Holdings in Q1 2021 and held it in 7 quarters.
Daniel Loeb's GeneDx Holdings position peaked at $21.2M in Q3 2021.
86 funds tracked by Wall St. Rank held GeneDx Holdings as of Q4 2022.

Based on Third Point's 13F filing for Q4 2022, filed 14 Feb 2023.